Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?
Agazzi
A
A
Rocca
P
P
Laszlo
D
D
Bodei
L
L
Grana
C
C
Martinelli
G
G
Paganelli
G
G
D018951:Antigens, CD20 / Q000097:blood*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes
D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide